# BOLT catalysts: Bolt Biotherapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/bolt/catalysts

> Bolt Biotherapeutics, Inc. (BOLT) has 1 upcoming catalyst. The next is the PRA-216 interim data readout, Q2 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for BOLT?

Bolt Biotherapeutics, Inc. (BOLT) has 1 upcoming catalyst. The next is the PRA-216 interim data readout, Q2 2027. Press release filed with the SEC (EX-99): "Initiated Phase 2 studies with PRA-216, a half-life-extended IL-4Rα/TSLP bispecific, in asthma, atopic dermatitis and chronic obstructive pulmonary disease with initial data expected in 2Q 2027" [Calendar and source filings](https://sec-api.dev/companies/bolt/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-458403, https://www.sec.gov/Archives/edgar/data/1641281/000119312526458403/bolt-ex99_1.htm (retrieved 2026-11-13). Last confirmed 2026-11-12. Cite: https://sec-api.dev/companies/bolt/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Bolt Biotherapeutics, Inc. |
| Ticker | BOLT (Nasdaq) |
| SEC CIK | 1641281 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/bolt |

## Cash runway

Cash $15.0M as of 2026-09-30; quarterly burn $3.1M; about 14.7 months of runway at that rate (XBRL company facts, accession 0001193125-26-458877).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Oct 2023 | [BDC-3042 trial start](https://sec-api.dev/pdufa/bdc-3042) | BOLT | broad range of solid tumors | completed | "In October 2023, we dosed the first patient with BDC-3042 in the Phase 1 dose-escalation study." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1641281/000119312526104121/bolt-20251231.htm)) |
| November 12, 2024 | [Bolt Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/bolt/catalysts) | BOLT |  | completed | "Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1641281/000095017024125376/bolt-ex99_1.htm)) |
| March 24, 2025 | [Bolt Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/bolt/catalysts) | BOLT |  | completed | "Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1641281/000095017025043869/bolt-ex99_1.htm)) |
| May 12, 2025 | [Bolt Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/bolt/catalysts) | BOLT |  | completed | "Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1641281/000095017025069153/bolt-ex99_1.htm)) |
| August 14, 2025 | [Bolt Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/bolt/catalysts) | BOLT |  | completed | "Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1641281/000164128125000006/bolt-ex99_1.htm)) |
| November 12, 2025 | [Bolt Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/bolt/catalysts) | BOLT |  | completed | "Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1641281/000119312525277521/bolt-ex99_1.htm)) |
| 1H 2026 | [BDC-4182 interim data readout](https://sec-api.dev/pdufa/bdc-4182) | BOLT |  | delayed | "We look forward to presenting initial data in the first half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1641281/000164128125000006/bolt-ex99_1.htm)) |
| March 12, 2026 | [Bolt Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/bolt/catalysts) | BOLT |  | completed | "Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1641281/000119312526104102/bolt-ex99_1.htm)) |
| May 12, 2026 | [Bolt Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/bolt/catalysts) | BOLT |  | completed | "Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1641281/000119312526219361/bolt-ex99_1.htm)) |
| Q3 2026 | [BDC-4182 interim data readout](https://sec-api.dev/pdufa/bdc-4182) | BOLT | gastric and gastroesophageal cancer | scheduled | "First-in-class immune-stimulating antibody conjugate BDC-4182 in Phase 1 dose escalation study, initial clinical data expected in 3Q 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1641281/000119312526104102/bolt-ex99_1.htm)) |
| August 11, 2026 | [Bolt Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/bolt/catalysts) | BOLT |  | completed | "Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1641281/000119312526344580/bolt-ex99_1.htm)) |
| November 12, 2026 | [Bolt Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/bolt/catalysts) | BOLT |  | completed | "Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1641281/000119312526458403/bolt-ex99_1.htm)) |
| Q2 2027 | [PRA-216 interim data readout](https://sec-api.dev/pdufa/pra-216) | BOLT |  | scheduled | "Initiated Phase 2 studies with PRA-216, a half-life-extended IL-4Rα/TSLP bispecific, in asthma, atopic dermatitis and chronic obstructive pulmonary disease with initial data expected in 2Q 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1641281/000119312526458403/bolt-ex99_1.htm)) |

## Drugs

- [BDC-3042](https://sec-api.dev/pdufa/bdc-3042): broad range of solid tumors
- [BDC-4182](https://sec-api.dev/pdufa/bdc-4182): gastric and gastroesophageal cancer
- [PRA-216](https://sec-api.dev/pdufa/pra-216): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/bolt/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "BOLT catalysts: Bolt Biotherapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/bolt/catalysts

```bibtex
@misc{secapidev_companies_bolt_catalysts_20261116,
  title        = {BOLT catalysts: Bolt Biotherapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/bolt/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_bolt_catalysts_20261116","title":"BOLT catalysts: Bolt Biotherapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/bolt/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
